TO OBSERVE THE EFFECT OF AYURVEDIC MEDICINE FOR THE TREATMENT OF KASA (STABLE CHRONIC BRONCHITIS)

CLINICAL EVALUATION OF CHITRAKA HARITAKI AND LAVANGADI VATI IN THE MANAGEMENT OF KAPHAJA KASA (STABLE CHRONIC BRONCHITIS)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020214

Enrollment

Registered

2019-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention1: Chitraka Haritaki (AFI Part-I 3:10

API Part-II Vol-I): Dose : 6 gm BD Dosage form:Avaleha Route of Administration:Oral Time of Administration: Twice daily Anupana :Warm water Packing form:Pet jar Duration of therapy:12 Weeks Interven

API Part-II Vol-III): Dose:250 mg QID Dosage form:Vati Route of Administration : Oral (To be kept in mouth till it dissolves) Time of Administration : Four times a day Duration of therapy:12 Weeks Co

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex aged between 18 to 65 years. 2.Patients suffering from Stable Chronic Bronchitis. (Chronic Bronchitis is defined as a cough that occurs every day with sputum production that lasts for at least three months, two years in a row). 3.Patients having FEV1 > 80%. 4.Patient willing and able to participate in the study for 16 weeks.

Exclusion criteria

Exclusion criteria: 1.Any other pulmonary diagnosis like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc. 2.Patients with uncontrolled Diabetes Mellitus (Blood Sugar Fasting > 250 mg/dl) 3.Patients with poorly controlled Hypertension ( >=160 / 100 mmHg). 4.Patients on prolonged ( > 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 5.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders etc). 6.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 7.Symptomatic patients with clinical evidence of Heart failure. 8.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL). 9.Alcoholics and/or drug abusers. 10.Patients who have completed participation in any other clinical trial during the past six months. 11.Any other condition which the Investigator thinks may jeopardize the study.

Design outcomes

Primary

Measure	Time frame
Change in Leicester Cough Questionnaire (LCQ) Scores.Timepoint: On baseline, 14th day, 28th day, 42th day, 56th day, 70th day, 84th day and 112th day	—

Secondary

Measure	Time frame
1.Quality of life outcome from St. Georgeâ??s Respiratory Questionnaire (SGRQ) Score. 2.Change in the clinical symptoms of Kaphaja Kasa (Stable Chronic Bronchitis). Timepoint: On baseline and 84th day	—

Countries

India

Contacts

Public ContactDR HARBANS SINGH

CENTRAL AYURVEDA RESEARCH INSTITUTE FOR RESPIRATORY DISORDERS

dr.harbans@rediffmail.com9501248820

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026